Macro Insights Weekly: Asia’s Covid stumble and fiscal response


Resurgence of Covid infections has been economically disruptive to several economies of Asia. Fiscal costs are rising this year, on top of the record debt incurred in 2020.
Taimur Baig, Radhika Rao31 May 2021
  • Thailand is dealing with infection resurgence with a fiscal package amounting to 3% of GDP
  • Malaysia is on its sixth fiscal package since the pandemic began
  • Singapore’s relatively modest fiscal support, reflects pandemic situation under control
  • Pandemic management and fiscal necessities go hand in hand
Photo credit: AFP Photo


Commentary: Covid stumble and fiscal response in Malaysia, Singapore, and Thailand

Resurgence of Covid infections has been economically disruptive to several economies of Asia. India’s pandemic resurgence (6371 new cases per million in May) has dominated the headlines, but the picture has been striking elsewhere in the region as well, especially in Malaysia (4211), the Philippines (1567), and Thailand (1144). Singapore and Taiwan’s May numbers (140 and 260, respectively) are not high by comparison, but are departures nonetheless from their outstanding records.





With vaccination rollout in progress (in varying pace), protocols in place to medically deal with current cases, along with the knowhow to keep businesses operating safely, the economic fallout from the ongoing episode ought to be considerably smaller than the contraction experienced last year. But smaller does not mean trivial, and additional policy support is warranted. Pandemic-induced fall in taxable economic activity and a rise in public spending to support individuals and firms caused deficits and debts to rise last year; the trend is not diminishing this year either. We look at three cases in the region:

Thailand

The Thai government is reported to be borrowing an additional amount of THB500bn (3% of GDP) this year. The government proposes to spend THB300bn as direct support to affected industries; THB30bn for pandemic-related medical supplies; the remaining THB170bn will go towards demand support measures. By the time the year is over, these measures would take Thailand’s debt/GDP ratio to over 59%, as per our estimates. Considering the delay in resuming tourism and events, the support measures are necessary, in our view, especially since not even 3% of the population has been vaccinated so far.

Malaysia

There has been a worrisome spike in cases in Malaysia lately, with lockdown measures in place. A stimulus package worth USD4.8bn (1¼% of GDP) was announced in March, which was the sixth package unveiled since the start of the COVID-19 pandemic. The package comprised of 20 strategic initiatives to boost economic growth, support businesses, and extend targeted assistance to the people and affected sectors. Much work to vaccinate the population is ahead, with only about 2.5% of the population receiving the necessary doses.

Singapore

Singapore is on alert and back to imposing mobility restrictions, but its pandemic situation is at a substantially improved footing compared to its neighbours. With a third of the population already in the vaccine net, only a modest support package (¼% of GDP) was rolled out recently to enhance wage subsidies and extend rental relief to affected workers and businesses. Pandemic management and fiscal necessities go hand in hand.

Taimur Baig


To read the full report, click here to Download the PDF.

Taimur Baig, Ph.D. 泰穆爾 貝格, Ph.D.

Chief Economist - G3 & Asia 集團首席經濟學家 - G3 及亞洲
taimurbaig@dbs.com

Radhika Rao

Economist – India, Indonesia, Thailand & Eurozone
radhikarao@dbs.com


Subscribe here to receive our economics & macro strategy materials.
To unsubscribe, please click here.
The information herein is published by DBS Bank Ltd. It is based on information obtained from sources believed to be reliable, but the Group does not make any representation or warranty, express or implied, as to its accuracy, completeness, timeliness or correctness for any particular purpose. Opinions expressed are subject to change without notice. Any recommendation contained herein does not have regard to the specific investment objectives, financial situation & the particular needs of any specific addressee. The information herein is published for the information of addressees only & is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate legal or financial advice. The Group, or any of its related companies or any individuals connected with the group accepts no liability for any direct, special, indirect, consequential, incidental damages or any other loss or damages of any kind arising from any use of the information herein (including any error, omission or misstatement herein, negligent or otherwise) or further communication thereof, even if the Group or any other person has been advised of the possibility thereof. The information herein is not to be construed as an offer or a solicitation of an offer to buy or sell any securities, futures, options or other financial instruments or to provide any investment advice or services. The Group & its associates, their directors, officers and/or employees may have positions or other interests in, & may effect transactions in securities mentioned herein & may also perform or seek to perform broking, investment banking & other banking or finan­cial services for these companies. The information herein is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation. Sources for all charts & tables are CEIC & Bloomberg unless otherwise specified.

DBS Bank Ltd., 12 Marina Blvd, Marina Bay Financial Center Tower 3, Singapore 018982. Tel: 65-6878-8888. Company Registration No. 196800306E. DBS Bank Ltd., Hong Kong SAR Branch, a company incorporated in Singapore with limited liability. 18th Floor, The Center, 99 Queen’s Road Central, Central, Hong Kong SAR.

The information set out in this website ("Information") is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of or located in any locality, state, country, or other jurisdiction (including but not limited to citizens or residents of the United States of America) where such distribution, publication, availability or use would be contrary to law or regulation. This Information is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction (including but not limited to the United States of America) where such an offer or solicitation would be contrary to law or regulation. This Information is published for general circulation only and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person. Visitors accessing this website should always seek advice from an independent financial adviser regarding the suitability of the Information referred to herein (taking into account the specific investment objectives, financial situation and/or particular needs of each person in receipt of the Information) before making any investment and/or any purchase in reliance of the Information. Please refer to the actual research publications for important disclaimers and disclosures, where applicable.